Evaluation of the Activity of Drugs Containing Human Cell Lines: Promising Approaches and Requirements of Regulatory Bodies
Abstract
This article analyzes the latest requirements of the US and European regulatory authorities for the assessment of the activity of preparations containing human cell lines (biomedical cell product analogues); it gives a review of methods and approaches to the assessment of activity used by manufacturers at different stages of clinical studies and for already registered preparations for cell therapy. Based on the presented data, the basic principles and criteria for the selection of various methods for assessing activity, as well as the interpretation of the results obtained, are formulated. The information presented in the article can be useful both to the manufacturers of biomedical cellular products in the Russian Federation, and to the representatives of regulatory bodies in the process of quality examination.
About the Authors
A. A. Chaplenko
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
E. V. Melnikova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
O. A. Rachinskaya
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
Yu. V. Olefir
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
References
1. Viswanathan С, Ramdasi S., Kulkami R., Bopardikar A. Quality Management in the Manufacture of Stem-Cell-Based-Products. J Stem Cells 2017; 12 (4): 191-199.
2. Приказ МЗ РФ от 19 января 2017 года N 14н «Об утверждении формы спецификации на биомедицинский клеточный продукт». / Prikaz MZ RF ot 19 yanvarya 2017 goda N 14n «Ob utverzhdenii formy spetsifikatsii na biomeditsinskiy kletochnyy produkt». [in Russian]
3. Stacey G. N, Connon C. J., Coopman K., Dickson A. J., Fuller В., Hunt C. J., Moore H. Preservation and stability of cell therapy products: recommendations from an expert workshop. Regenerative med 2017; 12 (5); 553-564.
4. Lipsitz Y. Y, Timmins N. E., Zandstra P. W. Quality cell therapy manufacturing by design. Natur biotechnol 2016; 34 (4); 393.
5. ICH Harmonised tripartite guideline specifications: test procedures and acceptance criteria for biotechnological/biological products Q6B. 10 March 1999.
6. Юнасова Т. H, Фадейкина О. В., Сидоренко Е. С, Суханова Л. Л., Шитикова О. Ю., Саркисян К. А. и др. Разработка и изучение отраслевого стандартного образца активности вакцины против краснухи. Биопрепараты. Профилактика, диагностика, лечение. — 2015. - № 3. - С. 49-53. / Yunasova Т. К, Fadeykina О. V., Sidorenko Е. S., Sukhanova L. L., Shitikova О. YU., Sarkisyan К. A. i dr. Razrabotka i izuchenie otraslevogo standartnogo obraztsa aktivnosti vaktsiny protiv krasnukhi. Biopreparaty. Profilaktika, diagnostika, lechenie 2015; 3: 49—53. [in Russian]
7. Олефир Ю.В. Меркулов В А., Воробьева M.C., Рукавишников А.В., Бондарев В.П., Шевцов В.А. Отечественный препарат иммуноглобулина человека для экстренной профилактики и лечения клещевого энцефалита. Иммунология. — 2015. — Т. 36. — № 6. — С. 353—357. Olejir Yu.V. Merkulov V.A., Vorob'eva M.S., Rukavishnikov A.V., Bondarev V.P., SHevtsov V.A. Otechestvennyy preparat immunoglobulina cheloveka dlya ekstrennoy profilaktiki i lecheniya kleshchevogo entsefalita. Immunologiya 2015; 36 (6); 353—357. [in Russian]
8. Еаврилова H. А., Черепушкин С. А., Рыкалина H. В., Обухов Ю. И. Разработка метода определения биологической активности препаратов эритропоэтина in vitro. Биопрепараты. Профилактика, диагностика, лечение. — 2016. — № 2. — С. 120—124. / Gavrilova N. А., Cherepushkin S. A., Rykalina N. V., Obukhov Yu. I. Razrabotka metoda opredeleniya biologicheskoy aktivnosti preparatov eritropoetina in vitro. Biopreparaty. Profilaktika, diagnostika, lechenie. 2016; 2; 120—124. [in Russian]
9. Pimpaneau V., Gianelli F., Trouvin J. H., Poiseau A. D. The challenges of potency assay development for cell-based medicinal products in Europe. Regul Rapp 2015; 12 (5): 5—10.
10. Guideline on human cell-based medicinal products. EMEA/CHMP/410869/2006.
11. Guideline on potency testing of cell based immunotherapy medicinal products for the treatment of cancer. EMA/CHMP/BWP/271475/2006rev.1.
12. Carmen J., Burger S. R., McCaman M., Rowley J. A. Developing assays to address identity, potency, purity and safety: cell characterization in cell therapy process development. Regenerat med 2012; 7 (1): 85—100.
13. Guidance for Industry Potency Tests for Cellular and Gene Therapy Products. https://www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Cellularand GeneTherapy/UCM243392.pdf
14. Phinney D. G. Functional heterogeneity of mesenchymal stem cells: implications for cell therapy. J Cell Biochem 2012; 113 (9): 2806—2812.
15. Bravery C. A., Carmen J., Fong T., Oprea W., Hoogendoorn K. H., Woda J., Van't Hof W. Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industry. Cytotherapy 2013; 15 (1): 9—19.
16. Guthrie K., Bruce A., Sangha N., Rivera E., Basu J. Potency evaluation of tissue engineered and regenerative medicine products. Trends in biotechnol 2013; 31 (9): 505—514.
17. Samsonraj R. M., Rai B., Sathiyanathan P., Puan K. J., Rötzschke O., Hui J. H., Cool S. M. Establishing criteria for human mesenchymal stem cell potency. Stem Cells 2015; 33 (6): 1878—1891.
18. Mattar P., Bieback K. Comparing the immunomodulatory properties of bone marrow, adipose tissue, and birth-associated tissue mesenchymal stromal cells. Frontiers in Immunol 2015; 6 (560): 1—8.
19. Luyten Frank, Cosimo De Bari, Francesco Dell'Accio. Marker genes for use in the identification of chondrocyte phenotypic stability and in the screening of factors influencing cartilage production. U.S. Patent Application No. 12/515488. 2010.
20. Cheever M. A., Higano C. S. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011; 17 (11): 3520—3526.
21. Chen G. L., Paplham P., McCarthy P. L. Remestemcel-L for acute graftversus- host disease therapy. Exp Opin Biol Ther 2014; 14 (2): 261—269.
22. Lehman N., Cutrone R., Raber A., Perry R., Van't Hof W., Deans R., Woda J. Development of a surrogate angiogenic potency assay for clinical- grade stem cell production. Cytotherapy 2012; 14 (8): 994—1004.
Review
For citations:
Chaplenko AA, Melnikova EV, Rachinskaya OA, Olefir YV. Evaluation of the Activity of Drugs Containing Human Cell Lines: Promising Approaches and Requirements of Regulatory Bodies. Antibiotiki i Khimioterapiya = Antibiotics and Chemotherapy. 2018;63(9-10):53-60. (In Russ.)
Views:
333
Email this article 